Satellos Bioscience (TSE:MSCL)
TSX:MSCL
Want to see TSE:MSCL full AI Analyst Report?
MSCL Stock Chart & Stats
C$11.91
C$0.01(1.16%)
At close: 4:00 PM EST
C$11.91
C$0.01(1.16%)
Day’s Range― - ―
52-Week RangeC$6.24 - C$18.98
Previous CloseN/A
Volume29.01K
Average Volume (3M)178.54K
Market Cap
C$167.07M
Enterprise ValueC$41.10M
Total Cash (Recent Filing)C$69.96M
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta1.42
Next Earnings
Aug 31, 2026EPS Estimate
-0.71Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.96
Shares Outstanding20,831,190
10 Day Avg. Volume239,110
30 Day Avg. Volume178,539
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)3.04
Price to Sales (P/S)0.00
P/FCF Ratio-3.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$30.08Price Target Upside152.58% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-2.88
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA debt-free capital structure materially lowers short-to-medium-term solvency risk and preserves flexibility for the company to raise equity or enter licensing partnerships without immediate interest burdens. This structural conservatism supports runway extension and strategic optionality over months.
Focused Therapeutic SpecializationA concentrated R&D focus on skeletal muscle diseases, notably Duchenne muscular dystrophy, creates deep domain expertise and a clear clinical pathway. This specialization supports durable competitive positioning in a high-unmet-need niche, aiding partner interest and targeted trial designs over the medium term.
Lean Operating StructureA small employee base reflects a lean operating model that can limit fixed-cost burn relative to larger peers. For a pre-revenue biotech, this structural thrift can extend cash runway and allow focused allocation to core programs, preserving value while clinical milestones are pursued.
Bears Say
Pre-revenue With Widening LossesSustained pre-revenue status combined with materially wider TTM losses indicates the business is not yet converting R&D into commercial receipts. Over 2–6 months this elevates financing dependency and execution risk: continued losses without visible revenue increases likelihood of dilutive financings.
Persistent Negative Free Cash FlowChronic negative free cash flow means the company funds operations via external capital rather than internal cash generation. This structural cash burn forces ongoing financing activity, which can dilute shareholders and constrain strategic choices if capital markets or partner deals slow over the medium term.
Weak Profitability And Volatile EquityDeeply negative ROE and volatile shareholders' equity point to persistent value erosion and significant capital transactions. Over months this signals heightened dilution and governance tradeoffs as management balances funding needs with R&D progress, raising long-term shareholder-risk from repeated financings.
Satellos Bioscience News
MSCL FAQ
What was Satellos Bioscience’s price range in the past 12 months?
Satellos Bioscience lowest stock price was C$6.24 and its highest was C$18.98 in the past 12 months.
What is Satellos Bioscience’s market cap?
Satellos Bioscience’s market cap is C$167.07M.
When is Satellos Bioscience’s upcoming earnings report date?
Satellos Bioscience’s upcoming earnings report date is Aug 31, 2026 which is in 79 days.
How were Satellos Bioscience’s earnings last quarter?
Satellos Bioscience released its earnings results on May 15, 2026. The company reported -C$0.729 earnings per share for the quarter, missing the consensus estimate of -C$0.675 by -C$0.054.
Is Satellos Bioscience overvalued?
According to Wall Street analysts Satellos Bioscience’s price is currently Undervalued.
Does Satellos Bioscience pay dividends?
Satellos Bioscience does not currently pay dividends.
What is Satellos Bioscience’s EPS estimate?
Satellos Bioscience’s EPS estimate is -0.71.
How many shares outstanding does Satellos Bioscience have?
Satellos Bioscience has 20,831,190 shares outstanding.
What happened to Satellos Bioscience’s price movement after its last earnings report?
Satellos Bioscience reported an EPS of -C$0.729 in its last earnings report, missing expectations of -C$0.675. Following the earnings report the stock price went down -0.201%.
Which hedge fund is a major shareholder of Satellos Bioscience?
Currently, no hedge funds are holding shares in TSE:MSCL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Satellos Bioscience Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
C$30.08 (152.58% Upside)
C$30.08 (152.58% Upside)
Blogger Sentiment
Bullish
TSE:MSCL Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth C$251.2K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-20.16%
12-Months-Change
Fundamentals
Return on Equity
-51.42%
Trailing 12-Months
Asset Growth
69.55%
Trailing 12-Months
Company Description
Satellos Bioscience
Satellos Bioscience Inc., a biotechnology firm established in 2018 and headquartered in Toronto, Canada, specializes in developing regenerative therapies for degenerative muscle diseases. The company primarily operates in Canada and Australia, utilizing its proprietary MyoReGenX platform – an automated microscopy system engineered to replicate the muscle stem cell environment outside the body. A key focus for Satellos is the discovery and development of a small molecule drug specifically aimed at treating Duchenne muscular dystrophy.
MSCL Stock 12 Month Forecast
Average Price Target
C$30.08
▲(152.58% Upside)
Technical Analysis
Arch Biopartners
―
Medicenna Therapeutics Corp
―
Helix BioPharma
―
ME Therapeutics Holdings, Inc.
―
Onco-Innovations Ltd.
―
Options Prices
Currently, No data available
---